Calix Networks SEC Filings

Calix, Inc. furnished an 8‑K stating it has publicly disseminated a stockholder letter and issued a press release with its financial results for the third quarter ended September 27, 2025. The materials discuss non‑GAAP metrics, including non‑GAAP gross margin, operating expenses, sales and marketing investments, research and development investments, general and administrative investments, effective income tax rate, net income (profitability), net income per diluted share, and free cash flow, with reconciliations to U.S. GAAP provided.

The information is furnished under Item 2.02 and is not deemed filed under the Exchange Act. The press release is attached as Exhibit 99.1 and the stockholder letter with reconciliations as Exhibit 99.2.

Carl Russo, a director and reported 10% owner of Calix, Inc. (CALX), received an award of stock options on 09/29/2025. The option grants the right to buy 10,329 shares of Calix common stock at an exercise price of $61.38 per share. The option becomes exercisable in stages with 25% vesting on each anniversary of the grant date, and the first vesting date is September 29, 2025, with the stated exercisable date for the option portion shown as September 29, 2026 and an expiration of September 29, 2035.

The filing reports the options as directly owned following the transaction, with 10,329 shares underlying the option recorded as beneficially owned. The Form 4 was signed by an attorney-in-fact on behalf of Mr. Russo on 10/01/2025. All details above are taken directly from the Form 4 disclosure.

CALIX, INC. Form 4 summary Michael Weening, President & CEO and a director, reported multiple option exercises and share sales on September 10-11, 2025. He exercised stock options with a $7.84 strike to acquire 176,000 shares in aggregate and reported underlying option holdings totaling 300,000, 292,010, and 274,000 shares after each exercise line. Concurrently he sold 176,000 shares at prices of $62 and $63 per share. The filing states 100% of the exercised options were vested and exercisable as of November 27, 2023, and the sales were effected under a Rule 10b5-1 trading plan adopted February 28, 2025. The report was signed by an attorney-in-fact on behalf of Mr. Weening on September 11, 2025.

Calix, Inc. (CALX) notice reports a proposed sale under Rule 144 of 18,010 common shares valued at $1,134,630 to be sold through Morgan Stanley Smith Barney on the NYSE on 09/11/2025. The filing shows these 18,010 shares were acquired the same day by stock option exercise from the issuer and paid in cash. The form also discloses multiple recent sales by Michael Weening totaling 581,990 shares sold across six transactions between 07/22/2025 and 09/10/2025 with gross proceeds shown per transaction. The filing does not provide the issuer address or additional narrative disclosures.

Form 144 filed for CALIX, INC. (CALX) discloses a proposed sale of 157,990 common shares to be executed through Morgan Stanley Smith Barney on the NYSE on 09/10/2025, with an aggregate market value of $9,803,370. The filer acquired these shares the same day by exercising stock options and paid cash. The filing also reports insider sales by Michael Weening totaling 424,000 shares in the prior three months for total gross proceeds of $24,342,000. The shares to be sold represent about 0.24% of the 65,303,995 shares outstanding.

Michael Weening, President & CEO and a director of Calix, Inc. (CALX), executed transactions on 09/04/2025 that involved exercising options and contemporaneous sales. He exercised 24,000 stock options with an exercise price of $7.84, resulting in an acquisition of 24,000 shares. The same day he sold 24,000 shares at $60 per share. After these transactions he beneficially owned 16,117 shares of common stock and continued to hold 450,000 outstanding stock options.

The Form 4 notes the options were fully vested on November 27, 2023, and the sales were effected pursuant to a Rule 10b5-1 trading plan adopted on February 28, 2025. The filing was signed on behalf of Mr. Weening by an attorney-in-fact on 09/08/2025.

Calix, Inc. insider sale notice: This Form 144 shows a proposed sale of 24,000 common shares to be executed through Morgan Stanley Smith Barney on the NYSE with an aggregate market value of $1,440,000. The securities were acquired the same day, 09/04/2025, by stock option exercise with cash paid on acquisition. The filer previously sold common shares on 08/28/2025 (126,000 shares, $7,560,000), 08/04/2025 (74,000 shares, $4,218,000), 07/23/2025 (108,000 shares, $6,064,000) and 07/22/2025 (92,000 shares, $5,060,000), as disclosed in the form. The filer certifies no undisclosed material adverse information.

Michael Weening, President & CEO and director of Calix, Inc. (CALX), reported option exercise and share sale on 08/28/2025. He exercised 126,000 stock options with a $7.84 exercise price and acquired 126,000 shares, then sold 126,000 shares at $60. After these transactions his reported beneficial ownership is 16,117 shares and he holds 474,000 options exercisable into common stock. The filing states 100% of the option shares were vested as of 11/27/2023 and that the sales were effected under a Rule 10b5-1 trading plan adopted 02/28/2025. The Form 4 was signed by an attorney-in-fact on 09/02/2025.

Cory Sindelar, Chief Financial Officer of Calix, Inc. (CALX), reported transactions on 08/28/2025 showing option exercise and contemporaneous sales under a Rule 10b5-1 plan. He exercised 10,000 stock options with a $5.05 exercise price, resulting in 10,000 shares being acquired. On the same date he sold 10,000 shares at $60. After those transactions he beneficially owned 76,555 shares directly. The filing also shows Sindelar holds options covering 245,000 underlying shares, with 100% of that option grant fully vested and exercisable as of October 1, 2021. The Form 4 states the sales were effected pursuant to a 10b5-1 trading plan adopted February 7, 2025.